Skip to main content

Day: May 10, 2023

Societe Generale: shares & voting rights as of 30 April 2023

SOCIETE GENERALE : Number of shares composing current share capital and Total number of voting rights as of 30/04/2023 Regulated Information Paris, 10 May 2023 Information about the total number of voting rights and shares pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulations.Date Number of shares composing current share capital Total number ofvoting rights30 April 2023 808,208,965Gross: 882,680,247Press contact: Jean-Baptiste Froville_+33 1 58 98 68 00_ jean-baptiste.froville@socgen.comFanny Rouby_+33 1 57 29 11 12_ fanny.rouby@socgen.com Societe Generale Societe Generale is one of the leading European financial services groups. Based on a diversified and integrated banking model, the Group combines financial strength and proven expertise in innovation with a strategy...

Continue reading

Supplement to the release: Inside information: Digitalist Group has signed a letter of intent to acquire the share majority in Open Communications International AB 10.5.2023

Digitalist Group Plc Inside information May 10th, 2023 at 18:15 Supplement to the release: Inside information: Digitalist Group has signed a letter of intent to acquire the share majority in Open Communications International AB 10.5.2023 Digitalist Group supplements the stock exchange release published on 10.5.2023 at 9:30: Inside information: Digitalist Group has signed a letter of intent to acquire the share majority in Open Communications International AB The stock exchange release is supplemented with Open Communications International AB’s key figures 2022 and 2021: Key figures of OC:  2022 2021Turnover (MSEK) 14 13EBITDA (MSEK) 1.4 0.3EBITDA% 10% 3%Balance sheet total (MSEK) 6.9 4.7Equity (MSEK) 2.8 1.6Liabilities (MSEK) 4.1 3.1Key figures are presented according to Swedish accounting standards. The supplemented...

Continue reading

Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split

EDISON, N.J., May 10, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 4:01 p.m. Eastern Time today, May 10, 2023. Hepion common stock will begin trading on a split-adjusted basis when the market opens on May 11, 2023 under the existing trading symbol “HEPA.” As a result of the reverse stock split, the CUSIP number for the Company’s common stock will now be 426897302. The reverse stock split was previously approved...

Continue reading

NOTICE REGARDING ORKELA UAB FINANCIAL STATEMENTS FOR THE 3-MONTH PERIOD OF 2023

NOTICE REGARDING ORKELA UABFINANCIAL STATEMENTS FOR THE 3-MONTH PERIOD OF 2023 Basic data about the Company UAB „Orkela“ (hereinafter – the Company) is a private limited liability company registered with the State Enterprise Centre of Registers on 24 September 2015. Legal address: Jogailos st. 4 , Vilnius. The Company has no branches or representative offices. The principal activity of the Company is real estate development and construction. The Company owns a land plot and building complex in Vilnius, at Vasario 16 st. 1.The Company is developing the educational real estate complex near Vilnius Church and Monastery of Apostles St. Philip and St. Jacob. The expected completion date is in year 2024. Highlights of 2023 first quarter events:On January and March 2023 the Company issued 5 573 units of secured non-convertible bonds each period...

Continue reading

Genmab Announces Financial Results for the First Quarter of 2023

May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 HighlightsGenmab revenue increased 35% compared to the first quarter of 2022, to DKK 2,854 million“In the first quarter of the year we continued to lay the groundwork for the potential approval of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Looking beyond this indication, together with our partner AbbVie Inc. (AbbVie), we are committed to a robust clinical development program, evaluating epcoritamab in a variety of patient populations and treatment settings including in frontline DLBCL,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. Financial Performance First Quarter of 2023Net sales of DARZALEX® by Janssen Biotech, Inc. (Janssen) were USD 2,264 million in the first three months of 2023 compared...

Continue reading

AirBoss Announces Results of Annual General Meeting

NEWMARKET, Ontario, May 10, 2023 (GLOBE NEWSWIRE) — AirBoss of America Corp. (TSX: BOS) (OTCQX: ABSSF) (the “Company”) announced today that the nominees listed in the April 6, 2023 Notice of Meeting and Management Information Circular of the Company were elected as directors of the Company at the Annual General Meeting held earlier today in Kitchener, Ontario (the “Meeting”). Detailed results of the vote for the election of directors and the appointment of auditors are set out below. Election of DirectorsNominee Votes For % For Votes Withheld % WithheldAnita Antenucci 10,684,368 99.30% 75,178 0.70%David Camilleri 10,678,559 99.25% 80,987 0.75%Mary Matthews 10,287,421 95.61% 472,125 4.39%Robert McLeish 10,552,895 98.08% 206,651 1.92%Stephen Ryan 10,676,124 99.22% 83,422 0.78%P. Grenville...

Continue reading

Prosafe SE: First quarter 2023 results

(Figures in brackets refer to the corresponding period in 2022.) EBITDA for the first quarter was negative USD 6.4 million, mainly driven by lower utilization with two vessels operating in Brazil during the quarter and costs related to contract preparations for new contracts in Brazil and the US Gulf of Mexico. The demand outlook in Prosafe’s core markets is favourable from 2024 and onwards, and a significant tightening of the market balance for high end vessels is expected. Operations, HSSE and backlogQ1 2023 utilisation of 28.6 (68.1) per cent, two out of seven vessels operating during the quarter Good operating and HSSE performance on all vessels  Backlog of USD 316 million (USD 117 million) at quarter endQ1 financials Revenues of USD 14.3 million (USD 35.5 million) and EBITDA of negative USD 6.4 million (positive USD 4.8 million)...

Continue reading

Hepsor AS consolidated unaudited interim report for Q1 2023

The consolidated sales revenue of Hepsor amounted to 6.0 million euros in the first quarter of 2023 and the net profit was 0.14 million euros (including a net profit attributable to the owners of the parent of 0.24 million euros). The handover of apartments in the Paevälja Hoovimajad project accounted for most of the sales revenue in the first quarter of 2023. Two apartment buildings with a total of 96 apartments were built as part of the project, of which the first 40 apartments were handed over to homebuyers at the end of 2022. An additional 34 apartments were handed over to homebuyers during the first quarter of 2023, and as at 31 March 2023 real rights agreements have been signed for 74 apartments (77%) and law of obligations agreements or written reservation agreements have been signed for 4 apartments (4%). The Group’s revenues and...

Continue reading

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2023

Positive results from interim analysis of vafidemstat’s PORTICO Phase IIb trial in Borderline Personality Disorder Recruiting patients in FRIDA trial with iadademstat in combination with gilteritinib in relapsed/refractory FLT3-mutant AML patientsORY-4001, a selective HDAC-6 inhibitor, nominated as clinical development candidate for neurological diseases such as Charcot-Marie-Tooth (CMT), Amyotrophic Lateral Sclerosis (ALS) and othersMADRID, Spain and BOSTON, May 10, 2023 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent developments. Dr Carlos Buesa, Oryzon’s...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.